Abstract 2140: The Tgfb-Whsc1 Axis Drives Macrophage To Myofibroblast Transition During Wound Repair

Abstract

During the proliferative phase of tissue repair macrophages can transition to myofibroblasts, which promote wound contraction and closure. The mechanisms that control this transition remain unknown and are not well studied. Here, using a combination of murine transgenic models of disease, loss of function approaches, pharmacologic inhibition in vivo, and single cell RNA sequencing (scRNA-seq) in human wounds, we identified that a histone methyltransferase, Whsc1, regulates the fibrotic gene program in macrophages during wound repair. Specifically, we identified that Whsc1 was upregulated in wound macrophages (CD3 - CD19 - NK1.1 - Ly6G - CD11b + ) in response to TGFβ. Genetic loss of TGFβ-mediated signaling as well as siRNA knockdown of Whsc1 in bone marrow derived macrophages (BMDMs) decreased TGFβ-dependent expression of Acta2, Col1a1, Col3a1 (p<0.05). Further, TGFβ stimulation resulted in increased Whsc1 and H3K36 dimethylation at fibrotic gene promoters in wound macrophages (p<0.05). Importantly, local pharmacologic inhibition of Whsc1 in vivo significantly impaired wound healing, suggesting that Whsc1 is critical for normal wound repair. We next examined the role of Whsc1 in pathologic healing conditions (i.e. diabetes) where the macrophage-myofibroblast transition is impaired. Whsc1 expression was decreased in human macrophages analyzed by scRNA-seq of diabetic wounds and in murine wound macrophages from a diabetic model (DIO) (p<0.05). Interestingly, in DIO BMDMs, Whsc1 did not traffic to fibrotic promoters after TGFβ treatment, but rather remained at NFkB-regulated inflammatory gene promoters ( Il1b, Il6, Tnf ). On further examination of this, using co-immunoprecipitation and proximity ligation assay in BMDMs, we demonstrated increased physical interaction between RelA and Whsc1 in diabetic macrophages. Knockdown of RelA in DIO macrophages increased Whsc1 enrichment at fibrotic promoters, suggesting RelA sequestered Whsc1 at inflammatory gene promoters (p<0.05). The identification of TGFβ-Whsc1 as a driver of macrophage-myofibroblast transition in normal and pathological tissues allows for development of novel therapies to improve tissue repair, and targeting RelA in macrophages may improve diabetic wound healing.